Overview
On 26 February 2019, orphan designation (EU/3/19/2144) was granted by the European Commission to Accelsiors Ltd, Hungary, for poly(N-acetyl, N-arginyl)glucosamine (also known as PAAG15A or SNSP113) for the treatment of cystic fibrosis.
Key facts
Active substance |
Poly(N-acetyl, N-arginyl)glucosamine
|
Intended use |
Treatment of cystic fibrosis
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/19/2144
|
Date of designation |
26/02/2019
|
Sponsor |
Accelsiors CRO and Consultancy Services Ltd
|
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: